En face OCT angiography demonstrates flow in early type 3 neovascularization (retinal angiomatous proliferation).
BACKGROUND
The characteristics of type 3 neovascularization (NV), also known as retinal angiomatous proliferation, have been well described clinically, as well as with fluorescein angiography (FA), indocyanine green angiography, and optical coherence tomography (OCT). OCT angiography (OCT-A) is a novel and non-invasive technique for imaging retinal microvasculature by detecting changes, with respect to time, in reflectivity related to blood flow.


METHODS
In this case series, we describe two patients who presented with type 3 NV and underwent clinical examination and multimodal imaging, including OCT-A.


RESULTS
In the first patient, OCT-A demonstrated flow within two separate lesions in the same eye, one of which was only weakly detected by FA. In the second patient, sequential OCT-A demonstrated a reduction in intralesional flow following intravitreal therapy.


CONCLUSIONS
OCT-A may have a role in the early diagnosis of type 3 NV and in assessing the response to treatment. Further studies are needed to determine sensitivity and specificity.
1] Vitreous Retina Macula Consultants of New York, New York, NY, USA [2] LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA [3] Moorfields Eye Hospital, London, UK.
K K
KK
Dansingani
1] Vitreous Retina Macula Consultants of New York, New York, NY, USA [2] LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA [3] Department of Ophthalmology, New York University School of Medicine, New York, NY, USA.
J
J
Naysan
1] Vitreous Retina Macula Consultants of New York, New York, NY, USA [2] LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA [3] Department of Ophthalmology, New York University School of Medicine, New York, NY, USA.
K B
KB
Freund
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab / Q000627:therapeutic use; D012039:Regional Blood Flow / Q000502:physiology; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D012171:Retinal Vessels / Q000502:physiology*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab